SCHEMBL2301632

SCHEMBL2301632

CCCN1Cc2c(Cl)ncnc2N1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4452856 0.71 HTR2A (0.36) HTR2AHTR2CHTR2B
SCHEMBL12776650 0.68 ENPP1 (0.46)
SCHEMBL2749135 0.58 FGFR1 (0.40)
SCHEMBL2077987 0.58 HTT (0.38) HTR2AHTR2CHTR2B
SCHEMBL3803152 0.58 NNMT (0.44) HTR2AHTR2CHTR2B
SCHEMBL29487134 0.58 NNMT (0.44) HTR2AHTR2CHTR2B
SCHEMBL31622284 0.58 MTOR (0.36)
SCHEMBL23228418 0.57 IDH1 (0.34)
SCHEMBL22308398 0.57 AKT1 (0.42)
SCHEMBL30022333 0.57 AKT1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2024360-B1 SUBSTITUTED PYRAZOLOPYRIMIDINES CEPHALON INC (US) 2013-04-03 EP disclosed
US-8354414-B2 Substituted bicyclic pyrimidines CEPHALON, INC (US) 2013-01-15 US disclosed
EP-2351751-A1 Substituted pyrazolopyrimidines CEPHALON, INC. (US) 2011-08-03 EP disclosed
US-7851468-B2 Substituted pyrazolo[3,4-d]pyrimidines CEPHALON, INC. (US) 2010-12-14 US disclosed
US-20070281949-A1 Substituted pyrazolopyrimidines CEPHALON, INC. (US) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281949-A1 Substituted pyrazolopyrimidines DPYD, P2RX5, P2RX6 HTR2A 370/4885HTR2C 404/4885HTR2B 336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.